23/10/2019 1:14 am Welcome to isteroids.com - BLOG

Saturday 19, Jun 2010

  Bevacizumab helpful in improving neurocognitive function with aggressive brain cancer

Posted By
Pin it Share on Tumblr

Bevacizumab helpful in improving neurocognitive function with aggressive brain cancerBevacizumab (Avastin) based therapy has the potential of making a real difference for patients with glioblastoma.

It was announced by Roche that phase II BRAIN study of bevacizumab alone or in combination with irinotecan chemotherapy for treating relapsed or progressive glioblastoma (GBM) suggested that the drug is effective.

As per William M. Burns, CEO of Roche’s Pharmaceuticals Division, Avastin is able to demonstrate its benefits for proving its worth as an effective treatment option for an increasing variety of cancers.

Monday 19, Oct 2009

  Survival rate increased with Avastin in recurrent glioblastoma affected patients

Posted By
Pin it Share on Tumblr

Survival rate increased with Avastin in recurrent glioblastoma affected patientsAccording to a recent study that was conduced at 11 centers across the country and published in the early online version of the Journal of Clinical Oncology, survival rate gets increased with Avastin in recurrent glioblastoma affected patients. It was revealed during the study that the targeted therapy Avastin, alone or in combination with CPT-11 (chemotherapy drug) can considerably increase progression-free survival times and survival rates in patients with a deadly form of recurrent brain cancer.

Dr. Timothy Cloughesy, director of the Neuro-Oncology Program at UCLA’s Jonsson Comprehensive Cancer Center and senior author of the study said that positive results from Avastin have promoted the FDA to an accelerated approval of Avastin in May 2009 for use in patients with recurrent glioblastomas.

Avastin is an angiogenesis inhibitor that neutralizes VEGF (vascular endothelial growth factor), which is a chemical signal stimulating the growth of new blood vessels and has already been approved for use in metastatic colorectal, breast, and kidney cancers as well as non-small cell lung cancer.